Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
Ipsen and Albireo declared today that they have signed a binding merger agreement under which Ipsen would buy Albireo, a pioneer in the development of bile-acid modulators for the treatment of cholestatic liver disorders in both children and adults. The…